Biotechnology
YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility Equivalent to European Union GMP
GAITHERSBURG, Maryland, Nov. 16, 2022 /PRNewswire/ -- YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics, today announced that...
2022-11-16 08:50
2226
Simcere and Idorsia enter into a licensing agreement for daridorexant in China
NANJING, China, Nov. 15, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simcere"), an innovation and R&D-driven pharmaceutical company,and Idorsia Ltd (SIX: IDIA, "Idorsia"), specialized in the discovery, development and commercialization of small molecules to transform the hori...
2022-11-16 08:32
2990
Island to present at World Antiviral Congress 2022
MELBOURNE, Australia, Nov. 15, 2022 /PRNewswire/ -- Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to advise that CEO and Managing Director, DrDavid Foster will present at the World Antiviral Congress 2022 inSan Diego, USA which ...
2022-11-15 21:00
1975
Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis
ANNAPOLIS, Md., Nov. 15, 2022 /PRNewswire/ -- Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it has completed the first cohort of its Phase2a clinical trial of AB-101a, a topical therapeutic candidate for mild-to-m...
2022-11-15 20:30
1463
Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer
* An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cancer in Phase I/II TORCH-2 Study of ATG-008 (onatasertib) in combination with toripalimab, regardless of PD-L1 status * Study builds on promising results of Phase II TORCH monotherapy study in HBV+ p...
2022-11-15 16:51
1545
Nona Biosciences Announces Attendance at PEGS Europe 2022
CAMBRIDGE, Mass., Nov. 15, 2022 /PRNewswire/ -- Nona Biosciences (a wholly-owned subsidiary of HBM Holdings, HKEX: 02142) announced that the Company is attending the 14th Protein and Antibody Engineering Summit (PEGS) in Barcelona, Spain, November 14-16, 2022. The booth is located at #54. Frank ...
2022-11-15 15:57
1610
Striving Together, Upgrading the Biopharma Industry - International Biopharma Industry Week Shanghai 2022 Kicks Off
SHANGHAI, Nov. 15, 2022 /PRNewswire/ -- On November 14, the opening ceremony of the second "International Biopharma Industry Week Shanghai" (hereinafter referred to as the "IBIWS 2022") took place in the Shanghai Zhangjiang Science Hall. Themed on "Striving Together, Upgrading the Biopharma Indus...
2022-11-15 14:17
1888
HARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATION
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2022 /PRNewswire/ -- Harbor BioMed (HKEX: 02142) today announced establishment of a wholly-owned subsidiary, Nona Biosciences, to provide next-generation antibody and biotherapeutic solutions to partners from discovery to IND. T...
2022-11-15 12:19
1785
Biotheus has entered into a license and collaboration agreement with Hansoh Pharma for its EGFR/MET bispecific antibody in the Greater China territory
ZHUHAI, China, Nov. 14, 2022 /PRNewswire/ -- Biotheus Inc., a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases, announced today that they have entered into a collaboration agreement with Hansoh Pharmaceuticals, for Biotheu...
2022-11-15 11:16
1983
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa * Early customers include GP offices and other community-based healthcare settings * Latest figures, released as part of World Diabetes Day, reveal that 1 in 10 adults are now living with diabetes and nearly ...
2022-11-14 23:24
2630
RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published
Strong preclinical data, recently published in the International Journal of Molecular Sciences, from eight U.S government-funded in-vivo opaganib studies, supports opaganib's potential as a nuclear radiation injury therapeutic for homeland security material threat medical countermeasures (MCM) an...
2022-11-14 20:06
2139
SENTINEL DIAGNOSTICS LAUNCHES SENTINAT® 200, THE FULLY AUTOMATED SAMPLE TO RESULT SYSTEM FOR THE DIAGNOSIS OF VIRAL INFECTIONS
MILAN, Nov. 14, 2022 /PRNewswire/ -- Sentinel CH. SpA today announced the launch ofSENTiNAT® 200, the fully automated sample to result system, and STAT-NAT® SN200 Real-Time PCR assays for the quantitative detection of 10 viruses.SENTiNAT® 200 and STAT-NAT® SN200 kits represent the ideal soluti...
2022-11-14 17:00
1721
Telix Acquires Optimal Tracers
MELBOURNE, Australia and INDIANAPOLIS, Ind., Nov. 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement withSacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochem...
2022-11-14 06:36
2920
Treadwell Therapeutics Announces A Presentation at the 2022 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor
NEW YORK, Nov. 11, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines cancer, today announced a presentation for CFI-402411, an oral, first-in-class inhibitor ofH ematopoieticProgenitor Kinase 1 (HPK1), a negative regulator of immune cell...
2022-11-11 22:09
15589
Telix to Present at Jefferies London Healthcare Conference 2022
MELBOURNE, Australia, Nov. 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a commercial-stage biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, advises that DrChristian Behrenbruch,...
2022-11-11 20:00
5507
J INTS BIO, Novel Oral 4th Generation EGFR TKI 'JIN-A02' - Phase 1/2 IND approved by US FDA
- First patient expected in December 2022 SEOUL, South Korea, Nov. 10, 2022 /PRNewswire/ -- J INTS BIO announced on November 9th that it had received approval from the US FDA for its Phase 1/2 clinical trial of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' in patients with advanced non-small ...
2022-11-11 10:30
2188
Bridgewest Group inks deal with Pfizer to acquire injectable manufacturing plant in Western Australia
MIAMI and PERTH, Australia, Nov. 11, 2022 /PRNewswire/ -- Global private investment firm,Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, is expanding its portfolio. Today, Bridgewest Group has announced the signing of a definitive agree...
2022-11-11 10:07
3520
Oncoshot and Novotech Partner to Offer Cancer Data Insights
SINGAPORE, Nov. 11, 2022 /PRNewswire/ -- Oncoshot and internationally recognised contract research organisation (CRO) Novotech have begun a partnership to enhance clinical trial management success. This collaborative partnership will grant exchange and insights into real-time population data bet...
2022-11-11 10:00
3373
Harbour BioMed Enters into a License and Collaboration Agreement with Moderna
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 10, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) today announced that Nona Biosciences, a subsidiary wholly owned by the Company, had entered into a license and collaboration agreement with ModernaTX, Inc. (NASDA...
2022-11-11 09:03
2361
Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting
- Oral presentation highlights preclinical data with ATG-031, an in-house discovered anti-CD24 monoclonal antibody,tracking to an investigational new drug (IND) filing in H1:2023 - Three poster presentations showcase preclinical data with three programs developed or discovered in-house,ATG-1...
2022-11-11 08:30
2379
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 320 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 298 media titles]
2024-04-15 17:33
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
[Picked up by 287 media titles]
2024-04-12 15:14
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
[Picked up by 274 media titles]
2024-04-15 08:00
LEGOLAND® School Challenge 2024 Expands Across Asia and Opens for Registration on April 15th
[Picked up by 273 media titles]
2024-04-11 11:00
Most Read
LEGOLAND® School Challenge 2024 Expands Across Asia and Opens for Registration on April 15th
2024-04-11 11:00
6274
XCMG Machinery Launches Premium G2 Crane Brand
2024-04-12 14:39
5310
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
2024-04-12 15:14
4406
Cognizant Teams with Shopify and Google Cloud To Transform Enterprise Retail
2024-04-09 12:01
3534
PENSKE AUTOMOTIVE GROUP TO EXPAND RETAIL AUTOMOTIVE PRESENCE INTO AUSTRALIA
2024-04-09 04:15
3292